The Impact of Menopausal Hormone Therapy on Liver and Biliary Tract Health
Aim: to provide summarized data on the relationship between menopausal hormone therapy (MHT) and liver health.Key points. A decrease in estrogen production during the menopausal transition and a deficiency of estrogen and progesterone during postmenopause significantly affect lipid and carbohydrate...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2025-08-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/1712 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849235667421233152 |
|---|---|
| author | A. O. Bueverov N. I. Tapilskaya |
| author_facet | A. O. Bueverov N. I. Tapilskaya |
| author_sort | A. O. Bueverov |
| collection | DOAJ |
| description | Aim: to provide summarized data on the relationship between menopausal hormone therapy (MHT) and liver health.Key points. A decrease in estrogen production during the menopausal transition and a deficiency of estrogen and progesterone during postmenopause significantly affect lipid and carbohydrate metabolism and can lead to impaired liver function. With age, the risk of developing metabolic-associated fatty liver disease (MAFLD) in women increases significantly, due to a combination of hormonal changes, a higher incidence of metabolic disorders, and age-related factors. In turn, MAFLD is associated with an increased risk of cardiovascular disease, diabetes mellitus and metabolic disorders. In the absence of well-timed hormonal support, postmenopausal women are at high risk of developing serious complications, therefore, it is extremely important to select MHT with a favorable efficacy and safety profile. The approach to prescribing MHT should take into account the patient’s medical history, individual characteristics, as well as the mode of drug administration, considering the minimum effective dose.Conclusion. Oral combination MHT provides positive metabolic effects through the first-pass metabolism but is not associated with additional health risks. |
| format | Article |
| id | doaj-art-09bc970acfe449da81135a23c95fc270 |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2025-08-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-09bc970acfe449da81135a23c95fc2702025-08-20T04:02:42ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732025-08-0135310411310.22416/1382-4376-2025-35-3-104-1131221The Impact of Menopausal Hormone Therapy on Liver and Biliary Tract HealthA. O. Bueverov0N. I. Tapilskaya1Moscow Regional Research Clinical Institute named after M.F. Vladimirsky (MONIKI)Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott; Saint Petersburg State Pediatric Medical UniversityAim: to provide summarized data on the relationship between menopausal hormone therapy (MHT) and liver health.Key points. A decrease in estrogen production during the menopausal transition and a deficiency of estrogen and progesterone during postmenopause significantly affect lipid and carbohydrate metabolism and can lead to impaired liver function. With age, the risk of developing metabolic-associated fatty liver disease (MAFLD) in women increases significantly, due to a combination of hormonal changes, a higher incidence of metabolic disorders, and age-related factors. In turn, MAFLD is associated with an increased risk of cardiovascular disease, diabetes mellitus and metabolic disorders. In the absence of well-timed hormonal support, postmenopausal women are at high risk of developing serious complications, therefore, it is extremely important to select MHT with a favorable efficacy and safety profile. The approach to prescribing MHT should take into account the patient’s medical history, individual characteristics, as well as the mode of drug administration, considering the minimum effective dose.Conclusion. Oral combination MHT provides positive metabolic effects through the first-pass metabolism but is not associated with additional health risks.https://www.gastro-j.ru/jour/article/view/1712estrogen deficiencymetabolic-associated fatty liver diseasecholelithiasislipid profilemenopausal hormone therapy |
| spellingShingle | A. O. Bueverov N. I. Tapilskaya The Impact of Menopausal Hormone Therapy on Liver and Biliary Tract Health Российский журнал гастроэнтерологии, гепатологии, колопроктологии estrogen deficiency metabolic-associated fatty liver disease cholelithiasis lipid profile menopausal hormone therapy |
| title | The Impact of Menopausal Hormone Therapy on Liver and Biliary Tract Health |
| title_full | The Impact of Menopausal Hormone Therapy on Liver and Biliary Tract Health |
| title_fullStr | The Impact of Menopausal Hormone Therapy on Liver and Biliary Tract Health |
| title_full_unstemmed | The Impact of Menopausal Hormone Therapy on Liver and Biliary Tract Health |
| title_short | The Impact of Menopausal Hormone Therapy on Liver and Biliary Tract Health |
| title_sort | impact of menopausal hormone therapy on liver and biliary tract health |
| topic | estrogen deficiency metabolic-associated fatty liver disease cholelithiasis lipid profile menopausal hormone therapy |
| url | https://www.gastro-j.ru/jour/article/view/1712 |
| work_keys_str_mv | AT aobueverov theimpactofmenopausalhormonetherapyonliverandbiliarytracthealth AT nitapilskaya theimpactofmenopausalhormonetherapyonliverandbiliarytracthealth AT aobueverov impactofmenopausalhormonetherapyonliverandbiliarytracthealth AT nitapilskaya impactofmenopausalhormonetherapyonliverandbiliarytracthealth |